Form 4 for MGNX MACROGENICS INC
Accepted 2022-05-17 00:00:00 ET · period of report 2022-05-16 · accession 0001125345-22-000049 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-17 | 2022-05-16 | MGNX | Koenig Scott | Pres, CEO, Dir | M - OptEx | $1.51 | +53.3K | 1.05M | +5% | +$80.4K |
| D | 2022-05-17 | 2022-05-16 | MGNX | Koenig Scott | Pres, CEO, Dir | M - OptEx | $1.51 | -53.3K | 0 | -100% | -$80.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-16 | M | A | 53,265 | $1.51 | 1,049,636 | D | — | — | (F1) The transaction represents an exercise and hold of options. The shares are jointly owned with reporting person's spouse. |
| 2 | Derivative | Employee stock option (right to buy) | 2022-05-16 | M | D | 53,265 | $1.51 | 0 | D | $1.51 · — to 2023-01-05 | 53,265 Common Stock | (F2) 12.5% of the shares underlying the grant became exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter. |